计算生物学
亲和力成熟
免疫原性
表位
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
重组DNA
生物
抗体
基因
化学
遗传学
2019年冠状病毒病(COVID-19)
医学
疾病
病理
传染病(医学专业)
作者
Veda Sheersh Boorla,Ranjana Chowdhury,Ranjani Ramasubramanian,Brandon Ameglio,Rahel Frick,Jeffrey J. Gray,Veda Sheersh Boorla
出处
期刊:Proteins
[Wiley]
日期:2022-10-08
卷期号:91 (2): 196-208
被引量:5
摘要
The continued emergence of new SARS-CoV-2 variants has accentuated the growing need for fast and reliable methods for the design of potentially neutralizing antibodies (Abs) to counter immune evasion by the virus. Here, we report on the de novo computational design of high-affinity Ab variable regions (Fv) through the recombination of VDJ genes targeting the most solvent-exposed hACE2-binding residues of the SARS-CoV-2 spike receptor binding domain (RBD) protein using the software tool OptMAVEn-2.0. Subsequently, we carried out computational affinity maturation of the designed variable regions through amino acid substitutions for improved binding with the target epitope. Immunogenicity of designs was restricted by preferring designs that match sequences from a 9-mer library of "human Abs" based on a human string content score. We generated 106 different antibody designs and reported in detail on the top five that trade-off the greatest computational binding affinity for the RBD with human string content scores. We further describe computational evaluation of the top five designs produced by OptMAVEn-2.0 using a Rosetta-based approach. We used Rosetta SnugDock for local docking of the designs to evaluate their potential to bind the spike RBD and performed "forward folding" with DeepAb to assess their potential to fold into the designed structures. Ultimately, our results identified one designed Ab variable region, P1.D1, as a particularly promising candidate for experimental testing. This effort puts forth a computational workflow for the de novo design and evaluation of Abs that can quickly be adapted to target spike epitopes of emerging SARS-CoV-2 variants or other antigenic targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI